{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T02:14:03Z","timestamp":1787451243272,"version":"build-2736575974"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2019.14977","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T11:31:36Z","timestamp":1573644696000},"page":"e1914977","source":"Crossref","is-referenced-by-count":60,"title":["Effect of Intranasal vs Intramuscular Naloxone on Opioid Overdose"],"prefix":"10.1001","volume":"2","author":[{"given":"Paul","family":"Dietze","sequence":"first","affiliation":[{"name":"Behaviours and Health Risks Program, Burnet Institute, Melbourne, Victoria, Australia"},{"name":"School of Public Health and Preventive Medicine, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Jauncey","sequence":"additional","affiliation":[{"name":"Uniting Medically Supervised Injecting Centre, Kings Cross, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Salmon","sequence":"additional","affiliation":[{"name":"Uniting Medically Supervised Injecting Centre, Kings Cross, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Mohebbi","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Faculty of Health, Deakin University, Burwood, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Latimer","sequence":"additional","affiliation":[{"name":"Uniting Medically Supervised Injecting Centre, Kings Cross, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"van Beek","sequence":"additional","affiliation":[{"name":"South Eastern Sydney Local Health District, New South Wales, Australia"},{"name":"Kirby Institute, University of New South Wales, Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"McGrath","sequence":"additional","affiliation":[{"name":"Justice Health Forensic Mental Health Network, New South Wales Health, Randwick, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Kerr","sequence":"additional","affiliation":[{"name":"Centre for Quality and Patient Safety, School of Nursing and Midwifery, Deakin University, Geelong, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2019,11,13]]},"reference":[{"issue":"2","key":"zoi190574r1","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMra1202561","article-title":"Management of opioid analgesic overdose.","volume":"367","author":"Boyer","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi190574r2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10903120290938797","article-title":"Intranasal administration of naloxone by paramedics.","volume":"6","author":"Barton","year":"2002","journal-title":"Prehosp Emerg Care"},{"issue":"1","key":"zoi190574r3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5694\/mja2.2005.182.issue-1","article-title":"Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose.","volume":"182","author":"Kelly","year":"2005","journal-title":"Med J Aust"},{"issue":"3","key":"zoi190574r4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/add.2008.103.issue-3","article-title":"Intranasal naloxone for the treatment of suspected heroin overdose.","volume":"103","author":"Kerr","year":"2008","journal-title":"Addiction"},{"issue":"12","key":"zoi190574r5","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1111\/add.2009.104.issue-12","article-title":"Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose.","volume":"104","author":"Kerr","year":"2009","journal-title":"Addiction"},{"issue":"5","key":"zoi190574r6","doi-asserted-by":"publisher","first-page":"788","DOI":"10.2105\/AJPH.2008.146647","article-title":"Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose.","volume":"99","author":"Doe-Simkins","year":"2009","journal-title":"Am J Public Health"},{"issue":"4","key":"zoi190574r7","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/add.v111.4","article-title":"Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?","volume":"111","author":"Strang","year":"2016","journal-title":"Addiction"},{"issue":"2","key":"zoi190574r8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jsat.2012.07.004","article-title":"Opioid overdose prevention with intranasal naloxone among people who take methadone.","volume":"44","author":"Walley","year":"2013","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"zoi190574r9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13346-012-0092-0","article-title":"A response to the opioid overdose epidemic: naloxone nasal spray.","volume":"3","author":"Wermeling","year":"2013","journal-title":"Drug Deliv Transl Res"},{"issue":"4","key":"zoi190574r10","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/FTD.0b013e3181816214","article-title":"Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers.","volume":"30","author":"Dowling","year":"2008","journal-title":"Ther Drug Monit"},{"issue":"10","key":"zoi190574r11","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/jcph.v56.10","article-title":"Pharmacokinetic properties and human use characteristics of an FDA-approved intranasal naloxone product for the treatment of opioid overdose.","volume":"56","author":"Krieter","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"zoi190574r12","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/add.v113.3","article-title":"Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: phase I healthy volunteer study.","volume":"113","author":"McDonald","year":"2018","journal-title":"Addiction"},{"issue":"7","key":"zoi190574r13","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00228-018-2443-3","article-title":"Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers.","volume":"74","author":"Skulberg","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"zoi190574r14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00228-016-2191-1","article-title":"Pharmacokinetics of a new, nasal formulation of naloxone.","volume":"73","author":"Tylleskar","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"zoi190574r15","doi-asserted-by":"crossref","DOI":"10.1111\/add.14552","article-title":"Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial.","author":"Skulberg","year":"2019","journal-title":"Addiction"},{"issue":"8","key":"zoi190574r16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.5694\/mja2.2005.182.issue-8","article-title":"Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose.","volume":"182","author":"Glaser","year":"2005","journal-title":"Med J Aust"},{"issue":"9263","key":"zoi190574r17","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"issue":"15","key":"zoi190574r20","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Statistical principles for clinical trials (ICH E9): an introductory note on an international guideline.","volume":"18","author":"Lewis","year":"1999","journal-title":"Stat Med"},{"issue":"3","key":"zoi190574r22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/j.0006-341X.2004.00225.x","article-title":"Shared frailty models for recurrent events and a terminal event.","volume":"60","author":"Liu","year":"2004","journal-title":"Biometrics"},{"key":"zoi190574r23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.drugalcdep.2016.12.013","article-title":"Rapid widespread distribution of intranasal naloxone for overdose prevention.","volume":"173","author":"Madah-Amiri","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"24","key":"zoi190574r24","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.2146\/ajhp130798","article-title":"Intranasal naloxone administration for treatment of opioid overdose.","volume":"71","author":"Robinson","year":"2014","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"zoi190574r25","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1177\/1073110518782954","article-title":"Government patent use to address the rising cost of naloxone: 28 U.S.C. \u00a7 1498 and Evzio.","volume":"46","author":"Wang","year":"2018","journal-title":"J Law Med Ethics"},{"issue":"6","key":"zoi190574r26","first-page":"101","article-title":"Community-based opioid overdose prevention programs providing naloxone\u2013United States, 2010.","volume":"61","author":"Wheeler","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"zoi190574r27","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/add.2005.100.issue-5","article-title":"Transient changes in behaviour lead to heroin overdose: results from a case-crossover study of non-fatal overdose.","volume":"100","author":"Dietze","year":"2005","journal-title":"Addiction"},{"issue":"4","key":"zoi190574r28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/09581590400027528","article-title":"The Sydney Medically Supervised Injecting Centre: reducing harm associated with heroin overdose.","volume":"14","author":"van Beek","year":"2004","journal-title":"Crit Public Health"},{"issue":"1","key":"zoi190574r29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13011-019-0195-4","article-title":"Higher doses of naloxone are needed in the synthetic opiod era.","volume":"14","author":"Moss","year":"2019","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"zoi190574r18","volume-title":"Protocols and Pharmacology","author":"Ambulance Service of New South Wales","year":"2011"},{"key":"zoi190574r19","volume-title":"Community Management of Opioid Overdose","author":"World Health Organization","year":"2014"},{"key":"zoi190574r21","volume-title":"Generalized Linear Mixed Models","author":"McCulloch","year":"2001"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2755306\/dietze_2019_oi_190574.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T21:44:21Z","timestamp":1612302261000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2755306"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2019,11,13]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.14977","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,13]]}}}